Pricing Log in Create free account
Saturday 17 October 2026 Export MCK’s income statement to Excel — free account

McKesson Corporation

MCK Healthcare Medical Distribution

McKesson Corporation’s revenue for fiscal 2026 (year ended March 2026) was $403.4 billion, up 12.4% from fiscal 2025. In the quarter to June 2026, revenue grew 7.72%, EPS fell 17.7%, free cash flow grew 66.4% and total debt rose 10.5%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years, revenue growth for ten.

1,006.92 8.28 +0.83%
Market cap
$116.4B
P/E
26.8×
Fwd P/E
18.3×
Dividend yield
0.34%
F-score
7/9
Altman Z
6.15
Beneish M
−2.34
Dividend safety
86/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

McKesson Corporation (MCK) SEC filings, changes and red flags

Red flags

Filings

Form Period Filed What it reports Flags
8-K Oct 6, 2026 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Aug 25, 2026 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-Q Jun 30, 2026 P1I2: 24 added · 51 removed · 52 modified
P2I1A: no material changes, the filing says
8-K Aug 5, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jul 22, 2026 5.07 Submission of matters to a vote of security holders
8-K Jun 29, 2026 5.02 Departure or appointment of directors or officers; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits Officer departure
8-K Jun 9, 2026 1.01 Entry into a material definitive agreement; 2.03 Creation of a direct financial obligation; 9.01 Financial statements and exhibits
10-K Mar 31, 2026 1: 11 added · 7 removed · 46 modified
1A: 6 added · 6 removed · 34 modified
7: 45 added · 29 removed · 77 modified
8-K May 7, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Apr 28, 2026 1.01 Entry into a material definitive agreement; 1.02 Termination of a material definitive agreement; 2.03 Creation of a direct financial obligation; 9.01 Financial statements and exhibits
8-K Apr 1, 2026 1.01 Entry into a material definitive agreement; 2.03 Creation of a direct financial obligation; 9.01 Financial statements and exhibits
8-K Mar 6, 2026 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Mar 3, 2026 5.02 Departure or appointment of directors or officers; 9.01 Financial statements and exhibits
10-Q Dec 31, 2025
8-K Feb 4, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Sep 30, 2025
8-K Nov 5, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Sep 23, 2025 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Sep 18, 2025 2.02 Results of operations and financial condition; 8.01 Other events; 9.01 Financial statements and exhibits
10-Q Jun 30, 2025
10-K Mar 31, 2025

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.